Hepatoprotective effect of mengkudu (Morinda citrifolia) on rats induced by doxorubicin

Rozana; I. Nyoman Ehrich Lister; Edy Fachrial; Sukirman Lie

Rozana Faculty of Medicine, Universitas Prima Indonesia, Medan, Sumatera Utara, Indonesia.
I. Nyoman Ehrich Lister Faculty of Medicine, Universitas Prima Indonesia, Medan, Sumatera Utara, Indonesia.
Edy Fachrial Faculty of Medicine, Universitas Prima Indonesia, Medan, Sumatera Utara, Indonesia.
Sukirman Lie Faculty of Medicine, Universitas Prima Indonesia, Medan, Sumatera Utara, Indonesia.

Abstract

The liver is the largest solid organ, the largest gland and one of the most vital organs that functions as a center for nutrient metabolism and excretion of waste metabolites. In general, the biological effects caused by the use of anthracycline doxorubicin are the occurrence of apoptosis, necrosis, and autophagy. The purpose of this study was to determine the hepatoprotective activity of mengkudu fruit ethanol extract against the rats induced by doxorubicin. Mengkudu fruit ethanol extract was obtained by maceration. Hepatoprotective activity test is done by measuring aspartate transaminase (AST) and alanine transaminase (ALT). Animals were induced with DOX 5 mg/kgbw on day 1, 7, 14 and 20^th. Administration of mengkudu extract 100 mg/kgbw, 300 mg/kgbw, and 500 mg/kgbw given from day 1 to day 20 and on the 21st day cardiac serum levels of AST and ALT were determined. Mengkudu dose of 100 mg/kgbw, 300 mg/kgbw and 500 mg/kgbw have hepatoprotective activity against male rats induced by doxorubicin. Mengkudu shows activity as a hepatoprotection. Mengkudu doses of 100, 300 and 500 mg/kgbw can inhibit the increase in ALT and AST activity. Mengkudu dose 100 mg/kgbw with AST 334.33 U/L and ALT 152 U/L, mengkudu dose 300 mg/kgbw with AST 304.33 U/L and ALT 117.33 U/L, and mengkudu dose 500 mg/kgbw with AST 192.67 U/L and ALT 103.67 U/L showed significant differences (p <0.05) against the negative control group. Mengkudu doses of 100, 300, and 500 mg/kgbw can reduce ALT and AST in doxorubicin-induced male rats.

Keywords: Hepatoprotective, Mengkudu, AST, ALT

Downloads

Download data is not yet available.

References

1. Assi R. A., et al. Morinda citrifolia (Mengkudu): A comprehensive review on its industrial uses, pharmacological activities, and clinical trials 2015; 6(8): 8-9.
2. Barret, K., Brooks, H., Boitano, S., dan Barman, S. Ganong’s Review of Medical Physiology. 23rd Edition. New York: McGraw Hill Companies 2010; 4(9): 481-482.
3. Bengaied, D., A. Ribeiro., M. Amri., D. Scherman., P. Arnau. Reduction of hepatotoxicity induced by doxorubicin. Journal of Integrative Oncology 2017; 9(6): 1-3.
4. Buchholz, Thomas A, David S, James S, Mark A, Jeffrey B, Lajos P. Global gene expression changes during neo adjuvant chemotherapy for human breast cancer. Cancer J. 2002; 8(6):41-88.
5. Burton, G. J., E.J auniaux. Oxidative stress. Best Practice and Research Clinical Obstetrics and Gynaecology. 2011; 25(3): 287-299.
6. Flore, M.S.H. Atlas of human histology. Fifth Edition. Philadelphia: Lea and Febiger. 1998; 5(9):93-100.
7. Hadi, E. H., R. Vettor., M. Rossato. Vitamin E as a treatment for nonalcoholic fatty liver disease: Reality of Myth?. Antioxidants 2018; 7(1): 1-12.
8. Hirazumi, A., Furrasawa, E., Chou, S.C., and Hokama, Y. Anticancer activity of Morinda citrifolia, L on Intraperitoneally Inplanted Lewis lungcarcinoma in syingenic mice, Proc. West PharmacolSoc, 1994; 37: 145-146.
9. Holt, A.dan Smith, A. An Introduction to the anatomy of the liver. In: Drugs and the Liver. Illinois: Pharmaceutical Press. 2008; 10(4): 5-15.
10. Junqueira, L., Carneiro, C.J., dan Kelley, R.O. Basic Histology. Seventh Edition. USA: Appleton and Lange. 1992; 5(9): 678-681.
11. Lamas, D. J. M., M. B. Nicoud., H. A. Sterle., E. Carabajal., F. Tesan., J. C. Perazzo, G. A. Cremaschi., E. S. Rivera., V. A. Medina. Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell Death Discovery 2015; 5(7): 50-59.
12. Lewis, P. N. Drugs and the liver. London: Pharmaceutical Press. 2008; 7(16): 59-60.
13. Li, S., Y. Tan., N. Wang., J. Z. Zhang., L. Lao., C. W. Wong., Y. Feng. The role of oxidative stress and antioxidants in liver disease. International Journal of Moleculer Sciences. 2015; 1(6): 26087-26124.
14. Luft, R. The development of mitochondrial medicine. Proc. Natl. Acad. Sci. U S A. 1994; 91(19):8731-8.
15. Kinjo, J., Okawa, M., dan Udayama, M. Hepatoprotective and hepatotoxic actions of oleanolic acid-type triterpenoidal glucuronides on rat primary hepatocyte cultures. Pharmaceutical Society of Japan. 1999; 47(2): 290-292.
16. Misih, S. R. Z. A., Bloomston. Liver Anatomi. Surg. Clin. North. Am. 2010; 90(4): 643-653.
17. Mohammad, A., M. Kenganora., S. N. Manjula. Health Benefits of Morinda citrifolia (Mengkudu): A Review. Pharmacognosy Journal. 2016; 8(4): 321-334.
18. Murli, K. Microscopic Anatomy of the Liver. Clinical Liver Disease. 2016; 2(1): 4-6.
19. Nirmala, M., Girija, K., Lakshman, K., dan Divya, T. Hepatoprotective activity of musa paradisiaca on experimental animal models. Asian Pasific Journal of Tropical Biomedicine 2016; 2(1): 11-20.
20. Price, S.A., dan Wilson L.M. Pathophysiology of Clinical Concepts of Disease Processes. Jakarta: EGC. 1996; 27(28): 426-433.